Founded in 2008, Gubra A/S operates through three synergistic business units: Biotech, CRO, and Ventures. The CRO segment provides highly specialized preclinical contract research services to global pharmaceutical and biotechnology companies, utilizing advanced in vivo pharmacology, 3D imaging, and bioinformatics. The Biotech segment leverages the company's proprietary AI-driven streaMLine platform to discover and develop peptide-based drug candidates, which are typically out-licensed to larger partners for clinical development. A notable example is its landmark out-licensing agreement with AbbVie for the anti-obesity asset GUBamy. By balancing service-based revenue with milestone payments from its proprietary pipeline, Gubra maintains a distinctive and sustainable approach to drug development.
